|
1
|
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
|
Lancet Oncol
|
2013
|
3.70
|
|
2
|
Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study.
|
J Clin Oncol
|
2008
|
2.06
|
|
3
|
Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report.
|
Neuro Oncol
|
2007
|
1.84
|
|
4
|
Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study.
|
Blood
|
2004
|
1.76
|
|
5
|
Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group.
|
J Clin Oncol
|
2005
|
1.76
|
|
6
|
Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.
|
J Clin Oncol
|
2008
|
1.75
|
|
7
|
Direct orthotopic transplantation of fresh surgical specimen preserves CD133+ tumor cells in clinically relevant mouse models of medulloblastoma and glioma.
|
Stem Cells
|
2008
|
1.64
|
|
8
|
A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study.
|
Clin Cancer Res
|
2007
|
1.61
|
|
9
|
Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC.
|
Mol Cancer Ther
|
2005
|
1.51
|
|
10
|
A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study.
|
J Neurooncol
|
2013
|
1.51
|
|
11
|
Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group.
|
J Clin Oncol
|
2011
|
1.45
|
|
12
|
Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report.
|
J Clin Oncol
|
2010
|
1.42
|
|
13
|
Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas.
|
J Clin Oncol
|
2006
|
1.40
|
|
14
|
A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study.
|
Pediatr Blood Cancer
|
2008
|
1.35
|
|
15
|
A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.
|
Clin Cancer Res
|
2012
|
1.33
|
|
16
|
Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study.
|
J Clin Oncol
|
2007
|
1.31
|
|
17
|
A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study.
|
Clin Cancer Res
|
2007
|
1.29
|
|
18
|
A clinically relevant orthotopic xenograft model of ependymoma that maintains the genomic signature of the primary tumor and preserves cancer stem cells in vivo.
|
Neuro Oncol
|
2010
|
1.24
|
|
19
|
Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines.
|
J Neurooncol
|
2007
|
1.21
|
|
20
|
Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report.
|
J Clin Oncol
|
2013
|
1.18
|
|
21
|
Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study.
|
J Clin Oncol
|
2007
|
1.17
|
|
22
|
Valproic Acid prolongs survival time of severe combined immunodeficient mice bearing intracerebellar orthotopic medulloblastoma xenografts.
|
Clin Cancer Res
|
2006
|
1.16
|
|
23
|
Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma.
|
Neuro Oncol
|
2008
|
1.15
|
|
24
|
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.
|
J Clin Oncol
|
2008
|
1.13
|
|
25
|
Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study.
|
Clin Cancer Res
|
2012
|
1.13
|
|
26
|
Nanoshell-mediated photothermal therapy improves survival in a murine glioma model.
|
J Neurooncol
|
2010
|
1.13
|
|
27
|
Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates.
|
Clin Cancer Res
|
2004
|
1.13
|
|
28
|
Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study.
|
J Clin Oncol
|
2005
|
1.11
|
|
29
|
Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity.
|
Mol Cancer Ther
|
2009
|
1.11
|
|
30
|
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.
|
Cancer Chemother Pharmacol
|
2005
|
1.10
|
|
31
|
Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.
|
Clin Cancer Res
|
2011
|
1.10
|
|
32
|
Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.
|
J Clin Oncol
|
2010
|
1.10
|
|
33
|
Characteristics and outcome of pediatric patients enrolled in phase I oncology trials.
|
Oncologist
|
2008
|
1.09
|
|
34
|
Expression analysis of juvenile pilocytic astrocytomas by oligonucleotide microarray reveals two potential subgroups.
|
Cancer Res
|
2005
|
1.09
|
|
35
|
A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas.
|
Eur J Cancer
|
2010
|
1.09
|
|
36
|
Incorporation of an enrichment program into a study protocol involving long-term restraint in macaques.
|
Lab Anim (NY)
|
2002
|
1.09
|
|
37
|
Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.
|
Blood
|
2007
|
1.07
|
|
38
|
Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group.
|
Clin Cancer Res
|
2010
|
1.07
|
|
39
|
Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium.
|
J Clin Oncol
|
2011
|
1.04
|
|
40
|
Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report.
|
J Clin Oncol
|
2006
|
1.03
|
|
41
|
Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.
|
Pediatr Blood Cancer
|
2010
|
1.03
|
|
42
|
A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group.
|
Eur J Cancer
|
2011
|
1.02
|
|
43
|
Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group.
|
Pediatr Blood Cancer
|
2013
|
1.01
|
|
44
|
Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018.
|
J Clin Oncol
|
2010
|
1.00
|
|
45
|
A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models.
|
Neuro Oncol
|
2010
|
1.00
|
|
46
|
Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
|
Cancer Chemother Pharmacol
|
2008
|
0.99
|
|
47
|
Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report.
|
Clin Cancer Res
|
2010
|
0.99
|
|
48
|
Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report.
|
J Clin Oncol
|
2010
|
0.99
|
|
49
|
Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study.
|
Cancer
|
2006
|
0.97
|
|
50
|
Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma.
|
Neuro Oncol
|
2013
|
0.95
|
|
51
|
A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916).
|
Pediatr Blood Cancer
|
2012
|
0.94
|
|
52
|
Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study.
|
Clin Cancer Res
|
2008
|
0.94
|
|
53
|
A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood.
|
Neuro Oncol
|
2008
|
0.94
|
|
54
|
Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study.
|
Pediatr Blood Cancer
|
2010
|
0.93
|
|
55
|
Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates.
|
Cancer Chemother Pharmacol
|
2009
|
0.93
|
|
56
|
Vascular-targeted photothermal therapy of an orthotopic murine glioma model.
|
Nanomedicine (Lond)
|
2012
|
0.93
|
|
57
|
A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study.
|
Pediatr Blood Cancer
|
2010
|
0.92
|
|
58
|
Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: a Children's Oncology Group study.
|
Pediatr Blood Cancer
|
2012
|
0.91
|
|
59
|
Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study.
|
Pediatr Blood Cancer
|
2008
|
0.91
|
|
60
|
Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group.
|
Pediatr Blood Cancer
|
2014
|
0.90
|
|
61
|
Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.
|
Pediatr Blood Cancer
|
2014
|
0.90
|
|
62
|
Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates.
|
Cancer Chemother Pharmacol
|
2004
|
0.90
|
|
63
|
Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group.
|
J Clin Oncol
|
2007
|
0.89
|
|
64
|
A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium report.
|
Clin Cancer Res
|
2012
|
0.89
|
|
65
|
Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study.
|
Cancer Chemother Pharmacol
|
2011
|
0.89
|
|
66
|
Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study.
|
J Clin Oncol
|
2007
|
0.89
|
|
67
|
Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).
|
Clin Cancer Res
|
2006
|
0.88
|
|
68
|
New approaches to drug development in pediatric oncology.
|
Cancer J
|
2005
|
0.88
|
|
69
|
Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors.
|
Clin Cancer Res
|
2003
|
0.88
|
|
70
|
A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study.
|
Pediatr Blood Cancer
|
2013
|
0.87
|
|
71
|
Proteomic profiling of cerebrospinal fluid identifies prostaglandin D2 synthase as a putative biomarker for pediatric medulloblastoma: A pediatric brain tumor consortium study.
|
Proteomics
|
2011
|
0.87
|
|
72
|
A phase I trial of MK-2206 in children with refractory malignancies: a Children's Oncology Group study.
|
Pediatr Blood Cancer
|
2014
|
0.86
|
|
73
|
Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates.
|
Cancer Chemother Pharmacol
|
2006
|
0.86
|
|
74
|
Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study.
|
J Clin Oncol
|
2007
|
0.86
|
|
75
|
A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL1112).
|
Clin Cancer Res
|
2013
|
0.86
|
|
76
|
Influence of phenytoin on the disposition of irinotecan: a case report.
|
J Pediatr Hematol Oncol
|
2002
|
0.86
|
|
77
|
Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors.
|
Pediatr Blood Cancer
|
2007
|
0.85
|
|
78
|
Reasons for participation in optional pharmacokinetic studies in children with cancer: a Children's Oncology Group phase 1 consortium study.
|
Pediatr Blood Cancer
|
2010
|
0.83
|
|
79
|
Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group.
|
Pediatr Blood Cancer
|
2014
|
0.83
|
|
80
|
Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group study.
|
Cancer
|
2009
|
0.83
|
|
81
|
Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia.
|
Cancer Chemother Pharmacol
|
2006
|
0.83
|
|
82
|
A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study.
|
Pediatr Blood Cancer
|
2008
|
0.83
|
|
83
|
A phase 1 study of vinblastine in combination with carboplatin for children with low-grade gliomas: a Children's Oncology Group phase 1 consortium study.
|
Neuro Oncol
|
2011
|
0.83
|
|
84
|
A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group.
|
J Neurooncol
|
2006
|
0.83
|
|
85
|
Plasma and cerebrospinal fluid pharmacokinetics of clofarabine in nonhuman primates.
|
Clin Cancer Res
|
2005
|
0.82
|
|
86
|
Phase 2 clinical trial of intrathecal topotecan in children with refractory leptomeningeal leukemia: a Children's Oncology Group trial (P9962).
|
Pediatr Blood Cancer
|
2011
|
0.82
|
|
87
|
Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis.
|
Cancer Chemother Pharmacol
|
2007
|
0.82
|
|
88
|
A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report.
|
Pediatr Blood Cancer
|
2015
|
0.81
|
|
89
|
Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study.
|
Clin Cancer Res
|
2005
|
0.81
|
|
90
|
A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children's Oncology Group phase I consortium study.
|
Pediatr Blood Cancer
|
2010
|
0.81
|
|
91
|
Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group.
|
Cancer Chemother Pharmacol
|
2008
|
0.81
|
|
92
|
Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates.
|
Cancer Chemother Pharmacol
|
2004
|
0.80
|
|
93
|
Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group.
|
Pediatr Blood Cancer
|
2010
|
0.80
|
|
94
|
Plasma and cerebrospinal fluid pharmacokinetics of rebeccamycin (NSC 655649) in nonhuman primates.
|
Cancer Chemother Pharmacol
|
2004
|
0.80
|
|
95
|
Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study.
|
Pediatr Blood Cancer
|
2006
|
0.80
|
|
96
|
Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines.
|
Pediatr Blood Cancer
|
2008
|
0.79
|
|
97
|
Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates.
|
Cancer Chemother Pharmacol
|
2007
|
0.79
|
|
98
|
Embryonal central nervous system neoplasms arising in infants and young children: a pediatric brain tumor consortium study.
|
Arch Pathol Lab Med
|
2011
|
0.78
|
|
99
|
Pharmacokinetics of intrathecal gemcitabine in nonhuman primates.
|
Clin Cancer Res
|
2002
|
0.77
|
|
100
|
Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer.
|
Cancer Chemother Pharmacol
|
2003
|
0.77
|
|
101
|
Phase I and pharmacokinetic study of thalidomide with carboplatin in children with cancer.
|
J Clin Oncol
|
2004
|
0.77
|
|
102
|
Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children's Oncology Group Phase I Consortium.
|
Pediatr Blood Cancer
|
2014
|
0.77
|
|
103
|
Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates.
|
Cancer Chemother Pharmacol
|
2006
|
0.76
|
|
104
|
Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas.
|
Neuro Oncol
|
2013
|
0.75
|
|
105
|
Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study.
|
Childs Nerv Syst
|
2015
|
0.75
|
|
106
|
Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376).
|
Pediatr Blood Cancer
|
2009
|
0.75
|
|
107
|
Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primates.
|
Cancer Chemother Pharmacol
|
2008
|
0.75
|
|
108
|
Phase I trial of irofulven (MGI 114) in pediatric patients with solid tumors.
|
Pediatr Blood Cancer
|
2006
|
0.75
|
|
109
|
Leptomeningeal cancer in the pediatric patient.
|
Cancer Treat Res
|
2005
|
0.75
|